iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
iBio (NASDAQ:IBIO) reported Q2 FY2026 results and a corporate update on Feb 10, 2026. The company closed a $26 million PIPE financing led by Frazier Life Sciences and received net proceeds of ~$24.4 million, extending cash runway into Q3 FY2028. Cash, cash equivalents and debt investments totaled $52.7 million as of Dec 31, 2025.
Preclinical progress includes NHP data for IBIO-610 (predicted human half-life up to 100 days), IBIO-600 toxicology nearing completion with Phase 1a planned in H1 2026, and ongoing CMC/toxicology to support IBIO-610 human trials in early 2027.
Positive
- $26M PIPE financing led by Frazier Life Sciences
- Net proceeds of approximately $24.4M extending cash runway into Q3 FY2028
- Cash and investments of $52.7M as of Dec 31, 2025
- IBIO-600 on track for Phase 1a in H1 2026
- IBIO-610 NHP data shows predicted human half-life up to 100 days
Negative
- No revenue recognized in Q2 FY2026 versus $0.2M prior-year quarter
- R&D expenses rose from $1.9M to $4.3M (increase of ~$2.4M)
- G&A expenses increased by ~$2.5M primarily from impairment of IBIO-101
News Market Reaction – IBIO
On the day this news was published, IBIO declined 2.64%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.3% during that session. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $52M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IBIO’s move occurred with mixed peer action: some biotech peers up (e.g., EVAX +1.76%), others down (e.g., LEXX -5.34%), and no peers in momentum scanners, pointing to stock-specific drivers.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q1 FY26 earnings | Positive | +0.8% | Reported Q1 results with major $50M offering and IBIO-610 NHP data. |
| Sep 05 | FY25 results | Positive | +2.9% | Fiscal 2025 results with obesity pipeline progress and $50M public offering. |
| May 02 | Q3 FY25 results | Negative | -1.9% | Q3 2025 loss widened alongside higher R&D and G&A expenses. |
| Feb 10 | Q2 FY25 results | Neutral | -7.3% | Q2 2025 results with modest revenue, net loss and new antibody programs. |
| Nov 12 | Q1 FY25 results | Neutral | -9.0% | Q1 2025 report showing no revenue but lower combined R&D and G&A. |
Earnings and financial updates have historically led to modest single‑digit moves, with an average reaction of about -2.91%, suggesting contained but often slightly negative responses.
Over the past year, iBio’s earnings releases have paired pipeline updates with balance sheet moves. Events on Nov 12, 2025 and Sep 5, 2025 highlighted financing steps and obesity antibody progress, drawing small positive reactions. Earlier quarters in 2025 showed net losses and higher R&D and G&A, with more mixed price responses. Today’s Q2 FY26 update continues the pattern of funding growth and advancing IBIO‑600 and IBIO‑610 toward first‑in‑human trials against a backdrop of rising operating spend.
Historical Comparison
Across five prior earnings or annual results, IBIO’s average move was -2.91%, usually modest. This Q2 FY26 update fits the pattern of pairing financials with pipeline and financing milestones.
Earnings updates show a progression from early obesity antibody discovery to more advanced IBIO-600 and IBIO-610 programs, funded through successive offerings that extend runway while moving toward first-in-human trials.
Regulatory & Risk Context
An effective S-3 filed on 2026-01-30 registers 11,061,738 shares from the January 2026 private placement for resale. iBio will not receive proceeds from these resales beyond nominal warrant exercise payments, but the filing may facilitate additional secondary share supply.
Market Pulse Summary
This announcement details Q2 FY26 financials and a corporate update that extends iBio’s cash runway into the third quarter of fiscal 2028 through a $26 million PIPE. The company reports no revenue while increasing R&D to advance IBIO-600 and IBIO-610 toward first-in-human studies. Investors may track cash levels of $52.7 million, the impact of higher G&A including impairment charges, and progress against timelines for Phase 1a and early 2027 clinical starts, alongside potential effects of registered resale shares.
Key Terms
PIPE financing financial
private placement financing financial
CMC technical
toxicology studies medical
non-human primate (NHP) medical
Phase 1a clinical trials medical
cardiometabolic medical
bispecific medical
AI-generated analysis. Not financial advice.
Secured
Progressed Pipeline with New Preclinical Data and Scientific Presentations at Leading Industry Conferences
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today reported financial results for the second quarter ended Dec. 31, 2025, and provided a corporate update on its progress.
“We have significantly advanced our preclinical pipeline programs - IBIO-610, our activin E antibody, and IBIO-600, our myostatin antibody - towards the start of human clinical trials by initiating CMC development and toxicology studies,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “Additionally, we recently completed a
Second Fiscal Quarter 2026 & Recent Corporate Updates:
- Closed a
$26 million private placement financing led by Frazier Life Sciences, announced on January 9th. The net proceeds from the raise are intended for the advancement of key preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, as well as general corporate purposes. With this funding the Company’s cash runway now extends into third quarter of fiscal year 2028. - Presented new non-human primate (NHP) data on IBIO-610, a potentially first-in-class Activin E antibody candidate, showing it has a predicted human half-life of up to 100 days. Such data supports potential dosing as infrequently as twice per year.
- Advanced preclinical pipeline across multiple programs:
- IBIO-610 NHP, CMC, and toxicology studies are ongoing and remain on track to support the commencement of first human clinical trials in early calendar year 2027.
- IBIO-600 is completing toxicology studies and is on track to enter Phase 1a clinical trials in the first half of calendar year 2026.
- Preclinical development efforts also continued for the Company’s bispecific myostatin × activin A program and amylin candidates.
- Delivered an oral presentation at the 2nd Annual Innovation in Obesity Therapeutics Summit on December 4, 2025, titled “Next-Generation Obesity Therapeutics: Long-Acting Antibodies for Improved Quality of Weight Loss.”
- Delivered an oral presentation at PepTalk, The Protein Science and Production Week event, on January 21, 2026, titled “Membrane Protein Targets Reengineered for Soluble Expression.”
- Delivered an oral presentation at the Keystone Symposia on Obesity Therapeutics on January 29, 2026, titled “Neutralization of Activin E Promotes Fat-Selective Weight Loss and Prevents Weight Regain in Preclinical Models of Obesity.”
Financial Results:
No revenue was recognized for the three months ending December 31, 2025. Revenue of
Research and Development (“R&D”) expenses for the three months ending December 31, 2025, and December 31, 2024, were
General and Administrative expenses for the three months ending December 31, 2025, and December 31, 2024, were approximately
iBio held cash, cash equivalents and investments in debt securities of
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding fulfilling iBio’s mission of reaching patients in need of an accessible, transformative therapy for obesity; executing iBio’s planned milestones and corporate priorities throughout 2026 and into 2027; the net proceeds of the private placement being used for the advancement of key preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, while extending the Company’s cash runway into third quarter of fiscal year 2028 and funding general corporate purposes; the potential of IBIO-610, a first-in-class Activin E antibody candidate, to have a human half-life of up to 100 days, supporting potentially dosing as infrequent as twice per year; the completion of NHP, CMC, and toxicology studies for IBIO-610; the commencement of first human clinical trials for IBIO-610 in early calendar year 2027; the completion of toxicology studies for IBIO-600; the entering Phase1a clinical trials for IBIO-600 by the first half of calendar year 2026; the continuation of development efforts for the Company’s bispecific myostatin × activin A program and amylin candidates; the Company’s ability to leverage AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases; iBio’s ability to combine its proprietary 3D modeling with its innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the potential of IBIO-610, a first-in-class Activin E antibody candidate, to have a human half-life of up to 100 days, supporting potentially dosing as infrequent as twice per year; the ability of iBio to complete NHP, CMC, and toxicology studies for IBIO-610; the ability of iBio to commence first in human clinical trials for IBIO-610 by early calendar year 2027; the ability of iBio to complete toxicology studies for IBIO-600; the ability of iBio to enter Phase 1a clinical trials for IBIO-600 by the first half of calendar year 2026; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
| iBio, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) | ||||||||
| December31, | June30, | |||||||
| 2025 | 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,672 | $ | 8,582 | ||||
| Accounts receivable - trade, net of allowance for credit losses of | — | — | ||||||
| Investments in debt securities (adjusted cost | 24,026 | — | ||||||
| Subscription receivable | — | 105 | ||||||
| Prepaid expenses and other current assets | 670 | 1,034 | ||||||
| Total Current Assets | 53,368 | 9,721 | ||||||
| Restricted cash | 228 | 210 | ||||||
| Promissory note receivable | 1,138 | 1,098 | ||||||
| Finance lease right-of-use assets, net of accumulated amortization | — | 68 | ||||||
| Operating lease right-of-use asset | 1,864 | 2,051 | ||||||
| Fixed assets, net of accumulated depreciation | 3,447 | 3,163 | ||||||
| Intangible assets, net of accumulated amortization | 4,338 | 6,848 | ||||||
| Security deposits | 10 | 26 | ||||||
| Total Assets | $ | 64,393 | $ | 23,185 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,654 | $ | 2,188 | ||||
| Accrued expenses | 1,579 | 1,345 | ||||||
| Finance lease obligations | — | 53 | ||||||
| Operating lease obligation - current portion | 518 | 490 | ||||||
| Equipment financing payable - current portion | — | 64 | ||||||
| Term promissory note | — | 766 | ||||||
| Contract liabilities | 1,150 | 1,200 | ||||||
| Total Current Liabilities | 5,901 | 6,106 | ||||||
| Operating lease obligation - net of current portion | 1,932 | 2,199 | ||||||
| Total Liabilities | 7,833 | 8,305 | ||||||
| Stockholders' Equity | ||||||||
| Series 2022 Convertible Preferred Stock - | — | — | ||||||
| Common Stock - | 30 | 19 | ||||||
| Additional paid-in capital | 403,457 | 347,085 | ||||||
| Accumulated other comprehensive loss | 10 | — | ||||||
| Accumulated deficit | (346,937 | ) | (332,224 | ) | ||||
| Total Stockholders’ Equity | 56,560 | 14,880 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 64,393 | $ | 23,185 | ||||
| iBio, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited; in thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | — | $ | 200 | $ | 100 | $ | 200 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 4,280 | 1,877 | 7,830 | 3,182 | ||||||||||||
| General and administrative | 5,165 | 2,742 | 7,666 | 5,543 | ||||||||||||
| Total operating expenses | 9,445 | 4,619 | 15,496 | 8,725 | ||||||||||||
| Operating loss | (9,445 | ) | (4,419 | ) | (15,396 | ) | (8,525 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 493 | 112 | 760 | 286 | ||||||||||||
| Interest expense | (41 | ) | (57 | ) | (77 | ) | (114 | ) | ||||||||
| Total other income | 452 | 55 | 683 | 172 | ||||||||||||
| Net loss | $ | (8,993 | ) | $ | (4,364 | ) | $ | (14,713 | ) | $ | (8,353 | ) | ||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (8,993 | ) | $ | (4,364 | ) | $ | (14,713 | ) | $ | (8,353 | ) | ||||
| Other comprehensive gain - unrealized gain on debt securities | 25 | — | 10 | — | ||||||||||||
| Comprehensive loss | $ | (8,968 | ) | $ | (4,364 | ) | $ | (14,703 | ) | $ | (8,353 | ) | ||||
| Loss per common share - basic and diluted | $ | (0.09 | ) | $ | (0.48 | ) | $ | (0.19 | ) | $ | (0.94 | ) | ||||
| Weighted-average common shares outstanding - basic and diluted - see Note 16 | 99,133 | 9,132 | 76,030 | 8,880 | ||||||||||||
FAQ
How much financing did iBio (IBIO) secure and who led the transaction?
What is iBio's cash position and how long is the runway after the January 2026 financing?
When will iBio's IBIO-600 and IBIO-610 programs enter human trials?
What preclinical data did iBio present for IBIO-610 at recent conferences?
How did iBio's expenses and revenue change in Q2 FY2026 compared with the prior year?
